Musculoskeletal Disorders Drugs Market By Drug Type (Analgesics, DMARDs, Corticosteroids, Others), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Online Providers, Drug Stores and Retail Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032

Musculoskeletal Disorders Drugs Market

Musculoskeletal drugs are medications used to treat various conditions affecting the musculoskeletal system, which includes bones, muscles, joints, ligaments, tendons, and cartilage. These drugs are used to manage a wide range of musculoskeletal disorders such as osteoarthritis, rheumatoid arthritis, osteoporosis, gout, fibromyalgia, and musculoskeletal pain. 

Key factors driving the growth of the musculoskeletal disorders drugs market include rise in prevalence of musculoskeletal (MSK) disorders such as rheumatoid arthritis, osteoporosis, and ankylosing spondylitis, increase in geriatric population, and rise in the number of pipeline drugs. Rheumatoid arthritis has become a major concern worldwide, as it is an autoimmune disease, which causes pain and inflammation of joints leading to limited mobility. Moreover, the prevalence of this disease has increased at an alarming rate across the globe. For instance, according to the Global RA Network, approximately, 1% of the world population lives with rheumatoid arthritis (RA), with at least twice as many women affected as men. Thus, surge in the prevalence of musculoskeletal (MSK) condition fuels the growth of the market. 

In addition, surge in adoption of analgesics and disease modifying anti-rheumatic drugs (DMARDs), availability of advanced healthcare facilities with trained medical professionals, and rise in number of research and development activities coupled with presence of major key players further drive the market growth. Furthermore, increase in awareness about early diagnosis and treatment of musculoskeletal disorders lead to a greater demand for drugs that treat these conditions and further drive the market growth. Moreover, easy availability of musculoskeletal disorder drugs, rise in potential pipeline candidates, and surge in approvals of biosimilar drugs such as Rituxan are anticipated to drive the growth of the market. 

Furthermore, higher healthcare expenditure and increase in product approvals for musculoskeletal disorders propel the market growth. For instance, in June 2022, Amgen announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI (rituximab-arrx) for adults with moderate to severely active rheumatoid arthritis. 

The market also offers growth opportunities to the key players in the market. Rise in number of pharmaceutical industries, and increase in demand for musculoskeletal disorders drugs which are anticipated to provide lucrative opportunities for the expansion of the market during the forecast period. In addition, several manufacturers focus on developing drugs for the treatment of psoriatic arthritis, and various arthritis treatments drugs are in pipeline at various stages of development which further support the market growth. For instance, Bimekizumab drug by UCB S.A. is in phase 3 trial for treatment of psoriatic arthritis. Thus, presence of drugs in the pipeline with ideal drugs in late stages of development is expected to provide lucrative opportunities for the growth of the market during the forecast period.   

The musculoskeletal disorders drugs market is segmented into drug type, route of administration, distribution channel, and region. On the basis of drug type, the market is categorized into analgesics, DMARDs, corticosteroids, and others. On the basis of route of administration, it is bifurcated into oral, and parenteral. On the basis of distribution channel, it is divided into hospital pharmacies, online providers, and drug stores and retail pharmacies. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA). 

The key players profiled in the study include AbbVie Inc., Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd. and UCB S.A. The players in the market have been actively engaged in the adoption various strategies such as product approval and product launch to remain competitive and gain advantage over the competitors in the market. For instance, in January 2022, AbbVie announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA), a systemic inflammatory disease that affects the skin and joints. 

Key Market Insights  

By drug type, the analgesics segment was the largest revenue contributor to the market and is estimated to reach $49,157.8 million by 2032, with a highest CAGR of 6.0%. 

By route of administration, the parenteral segment dominated the global market. However, the oral segment is expected to be the fastest-growing segment with a CAGR of 5.9% during the forecast period. 

Based on distribution channel, the drug stores and retail pharmacies segment was the largest revenue contributor to the market in 2022. However, the online providers segment is expected to be the fastest-growing segment with a CAGR of 5.6% during the forecast period.   

Based on region, North America garnered the largest revenue share in 2022, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

Overview

The musculoskeletal disorders drugs market valued for $83,474.24 million in 2022 and is estimated to reach $126,030.22 million by 2032, exhibiting a CAGR of 4.2% from 2023 to 2032.   

Musculoskeletal disorders (MSDs) affect the muscles, bones, and joints. These disorders cause pain, stiffness, and swelling in various parts of the body and they affect an ability of a person to perform daily activities. The symptoms of musculoskeletal disorders include stiff joints, swelling, and dull aches. These disorders may be caused by a variety of factors including repetitive motions, awkward postures, prolonged sitting or standing. MSDs affect people of all ages, but they are more common among the elderly and those who engage in physical activities that have stress on the musculoskeletal system, such as athletes and manual laborers. Some of the most common musculoskeletal disorders include rheumatoid arthritis, osteoporosis, osteoarthritis, and fibromyalgia.   

Musculoskeletal disorders drugs are a class of medications that are used to treat conditions affecting the muscles, bones, joints of body. These drugs help to alleviate pain, inflammation, and stiffness associated with musculoskeletal disorders such as rheumatoid arthritis, osteoporosis, and fibromyalgia. There are several types of musculoskeletal drugs including analgesics, corticosteroids, disease modifying anti rheumatic drugs, and corticosteroids.    

Increase in prevalence of musculoskeletal disorders such as rheumatoid arthritis osteoporosis, and ankylosing spondylitis, and surge in awareness toward availability of treatment for musculoskeletal disorders are the factors that contribute towards the growth of the market. Changes in lifestyle, such as longer working hours and increased physical activity, have resulted in a higher incidence of musculoskeletal disorders. This is anticipated to increase the demand for drugs that can effectively manage these conditions. For instance, according to Australian Institute of Health and Welfare, in 2020, it was reported that 3 in 5 individuals diagnosed with osteoarthritis. In addition, rise in geriatric population as they are more susceptible to musculoskeletal disorders, which resulted in a higher demand for drugs to manage these conditions and further drive the market growth. However, lack of access to treatment in underdeveloped countries, is expected to hamper the market growth.    

Moreover, the development of new drugs for musculoskeletal disorders, including biologics and biosimilars, has improved the efficacy and safety of treatment options. This led to an increase in the demand for these drugs. In addition, increase in awareness of musculoskeletal disorders among population, which led to more patients seeking medical attention and treatment for these conditions which supports the market growth.    

The global musculoskeletal disorders drugs market is segmented into drug type, route of administration, distribution channel, and region. On the basis of drug type, the market is categorized into analgesics, DMARDs, corticosteroids, and others. On the basis of route of administration, the market is bifurcated into oral, and parenteral. On the basis of distribution channel, the market is classified into hospital pharmacies, online providers, and drug stores & retail pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).   

Major key players that operate in the global musculoskeletal disorders drugs market are AbbVie Inc., Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd. and UCB S.A. Key players operating in the market have adopted product launch, and product approval as their key strategies to expand their product portfolio. For instance, in June 2022, Amgen announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI (rituximab-arrx), a biosimilar to Rituxan, in combination with methotrexate for adults with moderate to severely active rheumatoid arthritis. 

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the musculoskeletal disorders drugs market analysis from 2022 to 2032 to identify the prevailing musculoskeletal disorders drugs market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the musculoskeletal disorders drugs market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global musculoskeletal disorders drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ UCB S.A

Scope of Musculoskeletal Disorders Drugs Market Report

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research Methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

2.1. CXO Perspective

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.3.1. Bargaining power of suppliers

3.3.2. Bargaining power of buyers

3.3.3. Threat of substitutes

3.3.4. Threat of new entrants

3.3.5. Intensity of rivalry

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. High prevalence of musculoskeletal (MSK) disorders

3.4.1.2. Surge in geriatric population across the globe

3.4.1.3. Increase in number of pipeline drugs

3.4.2. Restraints

3.4.2.1. Lack of treatment in emerging countries

3.4.3. Opportunities

3.4.3.1. High growth potential in emerging markets

3.5. COVID-19 Impact Analysis on the market

4.1. Overview

4.1.1. Market size and forecast

4.2. Analgesics

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. DMARDs

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

4.4. Corticosteroids

4.4.1. Key market trends, growth factors and opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market share analysis by country

4.5. Others

4.5.1. Key market trends, growth factors and opportunities

4.5.2. Market size and forecast, by region

4.5.3. Market share analysis by country

5.1. Overview

5.1.1. Market size and forecast

5.2. Oral

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Parenteral

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospital Pharmacies

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Online Providers

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

6.4. Drug Stores and Retail Pharmacies

6.4.1. Key market trends, growth factors and opportunities

6.4.2. Market size and forecast, by region

6.4.3. Market share analysis by country

7.1. Overview

7.1.1. Market size and forecast By Region

7.2. North America

7.2.1. Key trends and opportunities

7.2.2. Market size and forecast, by Drug Type

7.2.3. Market size and forecast, by Route of Administration

7.2.4. Market size and forecast, by Distribution Channel

7.2.5. Market size and forecast, by country

7.2.5.1. U.S.

7.2.5.1.1. Key market trends, growth factors and opportunities

7.2.5.1.2. Market size and forecast, by Drug Type

7.2.5.1.3. Market size and forecast, by Route of Administration

7.2.5.1.4. Market size and forecast, by Distribution Channel

7.2.5.2. Canada

7.2.5.2.1. Key market trends, growth factors and opportunities

7.2.5.2.2. Market size and forecast, by Drug Type

7.2.5.2.3. Market size and forecast, by Route of Administration

7.2.5.2.4. Market size and forecast, by Distribution Channel

7.2.5.3. Mexico

7.2.5.3.1. Key market trends, growth factors and opportunities

7.2.5.3.2. Market size and forecast, by Drug Type

7.2.5.3.3. Market size and forecast, by Route of Administration

7.2.5.3.4. Market size and forecast, by Distribution Channel

7.3. Europe

7.3.1. Key trends and opportunities

7.3.2. Market size and forecast, by Drug Type

7.3.3. Market size and forecast, by Route of Administration

7.3.4. Market size and forecast, by Distribution Channel

7.3.5. Market size and forecast, by country

7.3.5.1. Germany

7.3.5.1.1. Key market trends, growth factors and opportunities

7.3.5.1.2. Market size and forecast, by Drug Type

7.3.5.1.3. Market size and forecast, by Route of Administration

7.3.5.1.4. Market size and forecast, by Distribution Channel

7.3.5.2. France

7.3.5.2.1. Key market trends, growth factors and opportunities

7.3.5.2.2. Market size and forecast, by Drug Type

7.3.5.2.3. Market size and forecast, by Route of Administration

7.3.5.2.4. Market size and forecast, by Distribution Channel

7.3.5.3. UK

7.3.5.3.1. Key market trends, growth factors and opportunities

7.3.5.3.2. Market size and forecast, by Drug Type

7.3.5.3.3. Market size and forecast, by Route of Administration

7.3.5.3.4. Market size and forecast, by Distribution Channel

7.3.5.4. Italy

7.3.5.4.1. Key market trends, growth factors and opportunities

7.3.5.4.2. Market size and forecast, by Drug Type

7.3.5.4.3. Market size and forecast, by Route of Administration

7.3.5.4.4. Market size and forecast, by Distribution Channel

7.3.5.5. Spain

7.3.5.5.1. Key market trends, growth factors and opportunities

7.3.5.5.2. Market size and forecast, by Drug Type

7.3.5.5.3. Market size and forecast, by Route of Administration

7.3.5.5.4. Market size and forecast, by Distribution Channel

7.3.5.6. Rest of Europe

7.3.5.6.1. Key market trends, growth factors and opportunities

7.3.5.6.2. Market size and forecast, by Drug Type

7.3.5.6.3. Market size and forecast, by Route of Administration

7.3.5.6.4. Market size and forecast, by Distribution Channel

7.4. Asia-Pacific

7.4.1. Key trends and opportunities

7.4.2. Market size and forecast, by Drug Type

7.4.3. Market size and forecast, by Route of Administration

7.4.4. Market size and forecast, by Distribution Channel

7.4.5. Market size and forecast, by country

7.4.5.1. Japan

7.4.5.1.1. Key market trends, growth factors and opportunities

7.4.5.1.2. Market size and forecast, by Drug Type

7.4.5.1.3. Market size and forecast, by Route of Administration

7.4.5.1.4. Market size and forecast, by Distribution Channel

7.4.5.2. China

7.4.5.2.1. Key market trends, growth factors and opportunities

7.4.5.2.2. Market size and forecast, by Drug Type

7.4.5.2.3. Market size and forecast, by Route of Administration

7.4.5.2.4. Market size and forecast, by Distribution Channel

7.4.5.3. Australia

7.4.5.3.1. Key market trends, growth factors and opportunities

7.4.5.3.2. Market size and forecast, by Drug Type

7.4.5.3.3. Market size and forecast, by Route of Administration

7.4.5.3.4. Market size and forecast, by Distribution Channel

7.4.5.4. India

7.4.5.4.1. Key market trends, growth factors and opportunities

7.4.5.4.2. Market size and forecast, by Drug Type

7.4.5.4.3. Market size and forecast, by Route of Administration

7.4.5.4.4. Market size and forecast, by Distribution Channel

7.4.5.5. South Korea

7.4.5.5.1. Key market trends, growth factors and opportunities

7.4.5.5.2. Market size and forecast, by Drug Type

7.4.5.5.3. Market size and forecast, by Route of Administration

7.4.5.5.4. Market size and forecast, by Distribution Channel

7.4.5.6. Rest of Asia-Pacific

7.4.5.6.1. Key market trends, growth factors and opportunities

7.4.5.6.2. Market size and forecast, by Drug Type

7.4.5.6.3. Market size and forecast, by Route of Administration

7.4.5.6.4. Market size and forecast, by Distribution Channel

7.5. LAMEA

7.5.1. Key trends and opportunities

7.5.2. Market size and forecast, by Drug Type

7.5.3. Market size and forecast, by Route of Administration

7.5.4. Market size and forecast, by Distribution Channel

7.5.5. Market size and forecast, by country

7.5.5.1. Brazil

7.5.5.1.1. Key market trends, growth factors and opportunities

7.5.5.1.2. Market size and forecast, by Drug Type

7.5.5.1.3. Market size and forecast, by Route of Administration

7.5.5.1.4. Market size and forecast, by Distribution Channel

7.5.5.2. Saudi Arabia

7.5.5.2.1. Key market trends, growth factors and opportunities

7.5.5.2.2. Market size and forecast, by Drug Type

7.5.5.2.3. Market size and forecast, by Route of Administration

7.5.5.2.4. Market size and forecast, by Distribution Channel

7.5.5.3. South Africa

7.5.5.3.1. Key market trends, growth factors and opportunities

7.5.5.3.2. Market size and forecast, by Drug Type

7.5.5.3.3. Market size and forecast, by Route of Administration

7.5.5.3.4. Market size and forecast, by Distribution Channel

7.5.5.4. Rest of LAMEA

7.5.5.4.1. Key market trends, growth factors and opportunities

7.5.5.4.2. Market size and forecast, by Drug Type

7.5.5.4.3. Market size and forecast, by Route of Administration

7.5.5.4.4. Market size and forecast, by Distribution Channel

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Top player positioning, 2022

9.1. AbbVie Inc.

9.1.1. Company overview

9.1.2. Key Executives

9.1.3. Company snapshot

9.1.4. Operating business segments

9.1.5. Product portfolio

9.1.6. Business performance

9.1.7. Key strategic moves and developments

9.2. Amgen Inc.

9.2.1. Company overview

9.2.2. Key Executives

9.2.3. Company snapshot

9.2.4. Operating business segments

9.2.5. Product portfolio

9.2.6. Business performance

9.2.7. Key strategic moves and developments

9.3. Eli Lilly and Company

9.3.1. Company overview

9.3.2. Key Executives

9.3.3. Company snapshot

9.3.4. Operating business segments

9.3.5. Product portfolio

9.3.6. Business performance

9.4. F. Hoffmann-La Roche Ltd.

9.4.1. Company overview

9.4.2. Key Executives

9.4.3. Company snapshot

9.4.4. Operating business segments

9.4.5. Product portfolio

9.4.6. Business performance

9.5. Johnson & Johnson

9.5.1. Company overview

9.5.2. Key Executives

9.5.3. Company snapshot

9.5.4. Operating business segments

9.5.5. Product portfolio

9.5.6. Business performance

9.5.7. Key strategic moves and developments

9.6. Merck & Co., Inc.

9.6.1. Company overview

9.6.2. Key Executives

9.6.3. Company snapshot

9.6.4. Operating business segments

9.6.5. Product portfolio

9.6.6. Business performance

9.7. Novartis AG

9.7.1. Company overview

9.7.2. Key Executives

9.7.3. Company snapshot

9.7.4. Operating business segments

9.7.5. Product portfolio

9.7.6. Business performance

9.7.7. Key strategic moves and developments

9.8. Pfizer Inc.

9.8.1. Company overview

9.8.2. Key Executives

9.8.3. Company snapshot

9.8.4. Operating business segments

9.8.5. Product portfolio

9.8.6. Business performance

9.8.7. Key strategic moves and developments

9.9. Teva Pharmaceutical Industries Ltd.

9.9.1. Company overview

9.9.2. Key Executives

9.9.3. Company snapshot

9.9.4. Operating business segments

9.9.5. Product portfolio

9.9.6. Business performance

9.9.7. Key strategic moves and developments

9.10. UCB S.A.

9.10.1. Company overview

9.10.2. Key Executives

9.10.3. Company snapshot

9.10.4. Operating business segments

9.10.5. Product portfolio

9.10.6. Business performanc

LIST OF TABLES

TABLE 01. GLOBAL MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 02. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR ANALGESICS, BY REGION, 2022-2032 ($MILLION)

TABLE 03. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR DMARDS, BY REGION, 2022-2032 ($MILLION)

TABLE 04. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR CORTICOSTEROIDS, BY REGION, 2022-2032 ($MILLION)

TABLE 05. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 06. GLOBAL MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 07. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)

TABLE 08. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR PARENTERAL, BY REGION, 2022-2032 ($MILLION)

TABLE 09. GLOBAL MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 10. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)

TABLE 11. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)

TABLE 12. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)

TABLE 13. MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)

TABLE 14. NORTH AMERICA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 15. NORTH AMERICA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 16. NORTH AMERICA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 17. NORTH AMERICA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 18. U.S. MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 19. U.S. MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 20. U.S. MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 21. CANADA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 22. CANADA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 23. CANADA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 24. MEXICO MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 25. MEXICO MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 26. MEXICO MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 27. EUROPE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 28. EUROPE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 29. EUROPE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 30. EUROPE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 31. GERMANY MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 32. GERMANY MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 33. GERMANY MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 34. FRANCE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 35. FRANCE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 36. FRANCE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 37. UK MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 38. UK MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 39. UK MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 40. ITALY MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 41. ITALY MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 42. ITALY MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 43. SPAIN MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 44. SPAIN MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 45. SPAIN MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 46. REST OF EUROPE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 47. REST OF EUROPE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 48. REST OF EUROPE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 49. ASIA-PACIFIC MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 50. ASIA-PACIFIC MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 51. ASIA-PACIFIC MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 52. ASIA-PACIFIC MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 53. JAPAN MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 54. JAPAN MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 55. JAPAN MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 56. CHINA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 57. CHINA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 58. CHINA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 59. AUSTRALIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 60. AUSTRALIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 61. AUSTRALIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 62. INDIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 63. INDIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 64. INDIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 65. SOUTH KOREA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 66. SOUTH KOREA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 67. SOUTH KOREA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 68. REST OF ASIA-PACIFIC MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 69. REST OF ASIA-PACIFIC MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 70. REST OF ASIA-PACIFIC MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 71. LAMEA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 72. LAMEA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 73. LAMEA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 74. LAMEA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 75. BRAZIL MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 76. BRAZIL MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 77. BRAZIL MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 78. SAUDI ARABIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 79. SAUDI ARABIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 80. SAUDI ARABIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 81. SOUTH AFRICA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 82. SOUTH AFRICA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 83. SOUTH AFRICA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 84. REST OF LAMEA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 85. REST OF LAMEA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 86. REST OF LAMEA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 87. ABBVIE INC.: KEY EXECUTIVES

TABLE 88. ABBVIE INC.: COMPANY SNAPSHOT

TABLE 89. ABBVIE INC.: PRODUCT SEGMENTS

TABLE 90. ABBVIE INC.: PRODUCT PORTFOLIO

TABLE 91. ABBVIE INC.: KEY STRATERGIES

TABLE 92. AMGEN INC.: KEY EXECUTIVES

TABLE 93. AMGEN INC.: COMPANY SNAPSHOT

TABLE 94. AMGEN INC.: PRODUCT SEGMENTS

TABLE 95. AMGEN INC.: PRODUCT PORTFOLIO

TABLE 96. AMGEN INC.: KEY STRATERGIES

TABLE 97. ELI LILLY AND COMPANY: KEY EXECUTIVES

TABLE 98. ELI LILLY AND COMPANY: COMPANY SNAPSHOT

TABLE 99. ELI LILLY AND COMPANY: PRODUCT SEGMENTS

TABLE 100. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO

TABLE 101. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES

TABLE 102. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT

TABLE 103. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS

TABLE 104. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO

TABLE 105. JOHNSON & JOHNSON: KEY EXECUTIVES

TABLE 106. JOHNSON & JOHNSON: COMPANY SNAPSHOT

TABLE 107. JOHNSON & JOHNSON: PRODUCT SEGMENTS

TABLE 108. JOHNSON & JOHNSON: PRODUCT PORTFOLIO

TABLE 109. JOHNSON & JOHNSON: KEY STRATERGIES

TABLE 110. MERCK & CO., INC.: KEY EXECUTIVES

TABLE 111. MERCK & CO., INC.: COMPANY SNAPSHOT

TABLE 112. MERCK & CO., INC.: PRODUCT SEGMENTS

TABLE 113. MERCK & CO., INC.: PRODUCT PORTFOLIO

TABLE 114. NOVARTIS AG: KEY EXECUTIVES

TABLE 115. NOVARTIS AG: COMPANY SNAPSHOT

TABLE 116. NOVARTIS AG: PRODUCT SEGMENTS

TABLE 117. NOVARTIS AG: PRODUCT PORTFOLIO

TABLE 118. NOVARTIS AG: KEY STRATERGIES

TABLE 119. PFIZER INC.: KEY EXECUTIVES

TABLE 120. PFIZER INC.: COMPANY SNAPSHOT

TABLE 121. PFIZER INC.: PRODUCT SEGMENTS

TABLE 122. PFIZER INC.: PRODUCT PORTFOLIO

TABLE 123. PFIZER INC.: KEY STRATERGIES

TABLE 124. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES

TABLE 125. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT

TABLE 126. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS

TABLE 127. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO

TABLE 128. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES

TABLE 129. UCB S.A.: KEY EXECUTIVES

TABLE 130. UCB S.A.: COMPANY SNAPSHOT

TABLE 131. UCB S.A.: PRODUCT SEGMENTS

TABLE 132. UCB S.A.: PRODUCT PORTFOLIO LIST OF FIGURES

FIGURE 01. MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032

FIGURE 02. SEGMENTATION OF MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032

FIGURE 03. TOP INVESTMENT POCKETS IN MUSCULOSKELETAL DISORDERS DRUGS MARKET (2023-2032)

FIGURE 04. HIGH BARGAINING POWER OF SUPPLIERS

FIGURE 05. MODERATE BARGAINING POWER OF BUYERS

FIGURE 06. MODERATE THREAT OF SUBSTITUTES

FIGURE 07. MODERATE THREAT OF NEW ENTRANTS

FIGURE 08. MODERATE INTENSITY OF RIVALRY

FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALMUSCULOSKELETAL DISORDERS DRUGS MARKET

FIGURE 10. MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022(%)

FIGURE 11. COMPARATIVE SHARE ANALYSIS OF MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR ANALGESICS, BY COUNTRY 2022 AND 2032(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR DMARDS, BY COUNTRY 2022 AND 2032(%)

FIGURE 13. COMPARATIVE SHARE ANALYSIS OF MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR CORTICOSTEROIDS, BY COUNTRY 2022 AND 2032(%)

FIGURE 14. COMPARATIVE SHARE ANALYSIS OF MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 15. MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022(%)

FIGURE 16. COMPARATIVE SHARE ANALYSIS OF MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR ORAL, BY COUNTRY 2022 AND 2032(%)

FIGURE 17. COMPARATIVE SHARE ANALYSIS OF MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR PARENTERAL, BY COUNTRY 2022 AND 2032(%)

FIGURE 18. MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022(%)

FIGURE 19. COMPARATIVE SHARE ANALYSIS OF MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 20. COMPARATIVE SHARE ANALYSIS OF MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 21. COMPARATIVE SHARE ANALYSIS OF MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 22. MUSCULOSKELETAL DISORDERS DRUGS MARKET BY REGION, 2022

FIGURE 23. U.S. MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 24. CANADA MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 25. MEXICO MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 26. GERMANY MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 27. FRANCE MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 28. UK MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 29. ITALY MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 30. SPAIN MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 31. REST OF EUROPE MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 32. JAPAN MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 33. CHINA MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 34. AUSTRALIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 35. INDIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 36. SOUTH KOREA MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 37. REST OF ASIA-PACIFIC MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 38. BRAZIL MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 39. SAUDI ARABIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 40. SOUTH AFRICA MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 41. REST OF LAMEA MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)

FIGURE 42. TOP WINNING STRATEGIES, BY YEAR

FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 46. COMPETITIVE DASHBOARD

FIGURE 47. COMPETITIVE HEATMAP: MUSCULOSKELETAL DISORDERS DRUGS MARKET

FIGURE 48. TOP PLAYER POSITIONING, 2022

FIGURE 49. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 50. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 51. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 52. AMGEN INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 53. AMGEN INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 54. ELI LILLY AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 55. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 56. F. HOFFMANN-LA ROCHE LTD.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 57. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 58. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 59. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)

FIGURE 60. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 61. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 62. MERCK & CO., INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 63. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 64. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 65. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)

FIGURE 66. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 67. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 68. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 69. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 70. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 71. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 72. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 73. UCB S.A.: NET SALES, 2020-2022 ($MILLION)

FIGURE 74. UCB S.A.: REVENUE SHARE BY REGION, 2022 (%